Working… Menu
Trial record 92 of 143 for:    NIFEDIPINE

Role of Calcium Channels in Vascular Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02885558
Recruitment Status : Active, not recruiting
First Posted : August 31, 2016
Last Update Posted : April 26, 2019
Information provided by (Responsible Party):
Stefan Mortensen, University of Southern Denmark

Brief Summary:
The purpose of this study is to examine the role of T-type calcium channels in endothelial dysfunction observed with ageing.

Condition or disease Intervention/treatment Phase
Endothelium, Vascular Drug: Efonidipine Drug: Nifedipine Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Role of T-type Calcium Channels in Vascular Function
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : July 25, 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Arm Intervention/treatment
Experimental: L + T-type
8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
Drug: Efonidipine
8 weeks treatment with either efonidipine
Other Name: Landel (efonidipine)

Active Comparator: L-Type
8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
Drug: Nifedipine
8 weeks treatment with either nifedipine
Other Name: Adalat (nifedipine)

Primary Outcome Measures :
  1. Vascular function [ Time Frame: 8 weeks ]
    Hemodynamic response to femoral arterially infused vasoactive substances

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 20 - 30 and 60-70
  • BMI < 30

Exclusion Criteria:

  • Hypertension (>150/90 mmHg)
  • Smoking
  • Physical activity >2 hours/week
  • Known chronic diseases
  • Pregnancy or birth within 3 month
  • Alcohol misuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02885558

Layout table for location information
Centre for Phsical Activity Research
Copenhagen, Denmark, 2100
Cardiovascular and Renal Research
Odense, Denmark, 5000
Sponsors and Collaborators
University of Southern Denmark

Layout table for additonal information
Responsible Party: Stefan Mortensen, Associate Professor, University of Southern Denmark Identifier: NCT02885558     History of Changes
Other Study ID Numbers: 47880
First Posted: August 31, 2016    Key Record Dates
Last Update Posted: April 26, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Stefan Mortensen, University of Southern Denmark:
Receptors, Calcium Channel Blocker
Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium, Dietary
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Antihypertensive Agents
Natriuretic Agents